Spotlight on Quetiapine in Acute Mania and Depression Associated with Bipolar Disorder

Authors: Dando, Toni M.¹; Keating, Gillian M.¹

Source: CNS Drugs, Volume 20, Number 5, 2006 , pp. 429-431(3)

Publisher: Adis International

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Quetiapine (Seroquel^®), an atypical antipsychotic with established efficacy in the treatment of schizophrenia, shows efficacy in the treatment of acute mania and depression associated with bipolar disorder.

Quetiapine, either as monotherapy or in combination with lithium or divalproex sodium (valproate semisodium), is generally well tolerated and effective in reducing manic symptoms in adult and adolescent patients with acute bipolar mania, and is approved for use in adults for this indication. As monotherapy, the drug is also effective in reducing depressive symptoms in patients with bipolar depression. It is associated with a low incidence of extrapyramidal symptom (EPS)-related adverse events and low EPS ratings in bipolar disorder. Quetiapine thus shows potential in the treatment of bipolar depression, and represents a useful agent for the treatment of acute bipolar mania.

Keywords: Adis Spotlights; Antipsychotics; Antipsychotics; Antipsychotics; Antipsychotics; Bipolar disorders; Quetiapine; Quetiapine; Quetiapine; Quetiapine

Document Type: Research article

Affiliations: 1: Adis International Limited, Auckland, New Zealand

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$57.95 plus tax Refund Policy